Arboviral Diseases Branch, Division of Vector-Borne Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, United States of America.
WHO consultant, Berlin, Germany.
PLoS Negl Trop Dis. 2022 Sep 6;16(9):e0010770. doi: 10.1371/journal.pntd.0010770. eCollection 2022 Sep.
Early detection of human yellow fever (YF) infection in YF-endemic regions is critical to timely outbreak mitigation. African National Laboratories chiefly rely on serological assays that require confirmation at Regional Reference Laboratories, thus delaying results, which themselves are not always definitive often due to antibody cross-reactivity. A positive molecular test result is confirmatory for YF; therefore, a standardized YF molecular assay would facilitate immediate confirmation at National Laboratories. The WHO-coordinated global Eliminate Yellow Fever Epidemics Laboratory Technical Working Group sought to independently evaluate the quality and performance of commercial YF molecular assays relevant to use in countries with endemic YF, in the absence of stringent premarket assessments. This report details a limited laboratory WHO-coordinated evaluation of the altona Diagnostics RealStar Yellow Fever Virus RT-PCR kit 1.0.
Specific objectives were to assess the assay's ability to detect YF virus strains in human serum from YF-endemic regions, determine the potential for interference and cross-reactions, verify the performance claims as stated by the manufacturer, and assess usability. RNA extracted from normal human serum spiked with YF virus showed the assay to be precise with minimal lot-to-lot variation. The 95% limit of detection calculated was approximately 1,245 RNA copies/ml [95% confidence interval 497 to 1,640 copies/ml]. Positive results were obtained with spatially and temporally diverse YF strains. The assay was specific for YF virus, was not subject to endogenous or exogenous interferents, and was clinically sensitive and specific. A review of operational characteristics revealed that a positivity cutoff was not defined in the instructions for use, but otherwise the assay was user-friendly.
The RealStar Yellow Fever Virus RT-PCR kit 1.0 has performance characteristics consistent with the manufacturer's claims and is suitable for use in YF-endemic regions. Its use is expected to decrease YF outbreak detection times and be instrumental in saving lives.
在黄热病(YF)流行地区,及早发现人类 YF 感染对于及时减轻疫情至关重要。非洲国家实验室主要依赖血清学检测,这些检测需要在区域参考实验室进行确认,从而导致结果延迟,而且由于抗体交叉反应,结果本身并不总是确定的。分子检测阳性结果可确认 YF;因此,标准化的 YF 分子检测方法将有助于国家实验室立即确认。世界卫生组织协调的全球消除黄热病疫情实验室技术工作组试图在没有严格的上市前评估的情况下,独立评估与流行地区使用相关的商业 YF 分子检测方法的质量和性能。本报告详细介绍了世界卫生组织协调的一项有限实验室评估,评估了 altona Diagnostics RealStar 黄热病病毒 RT-PCR 试剂盒 1.0 在检测来自黄热病流行地区的人类血清中的 YF 病毒株方面的能力,确定了潜在的干扰和交叉反应,验证了制造商所述的性能声称,并评估了可用性。从 YF 病毒污染的正常人类血清中提取的 RNA 表明该检测方法具有很高的精确性,批间差异最小。计算得出的 95%检测限约为 1,245 个 RNA 拷贝/ml [95%置信区间 497 至 1,640 拷贝/ml]。该检测方法对来自不同地理区域和不同时间的 YF 毒株均呈阳性。该检测方法对 YF 病毒具有特异性,不受内源性或外源性干扰物的影响,具有临床敏感性和特异性。对操作特性的审查表明,使用说明中未定义阳性截断值,但该检测方法易于使用。
RealStar 黄热病病毒 RT-PCR 试剂盒 1.0 的性能与制造商的声称一致,适用于黄热病流行地区。它的使用有望减少 YF 疫情的检测时间,并有助于挽救生命。